Kevin DeGeeter

Kevin DeGeeter has rejoined Ladenburg Thalmann as a Managing Director in our Equity Research department, effective June 2025. In this role, Kevin will lead equity research coverage of oncology, infectious disease, and cell therapy companies, focusing on businesses with market capitalizations ranging from $50 million to $5 billion. Kevin brings over 20 years of experience in both buyside and sell side research, with a strong track record in biotechnology and molecular diagnostics. Prior to rejoining Ladenburg Thalmann, he was an Analyst at Oppenheimer & Co., where he covered small-cap molecular diagnostics and biotech stocks. His career also includes roles at J.P. Morgan, PaineWebber, Natexis Bleichroeder, and Manning & Napier Advisors. In addition to his research credentials, Kevin served as CFO of Nabsys, a life science tools company that was later acquired by Hitachi Ltd. Kevin holds a BA in Economics from Colgate University.